Autophagy: a killer or guardian of vascular smooth muscle cells.


Journal

Journal of drug targeting
ISSN: 1029-2330
Titre abrégé: J Drug Target
Pays: England
ID NLM: 9312476

Informations de publication

Date de publication:
06 2020
Historique:
pubmed: 15 12 2019
medline: 20 8 2021
entrez: 15 12 2019
Statut: ppublish

Résumé

Vascular smooth muscle cells (VSMCs) is one of the main intracellular components of the blood vessel wall. The abnormalities of VSMCs participate in the development of cardiovascular diseases such as atherosclerosis, hypertension, and restenosis, especially the formation and stability of atherosclerotic plaques. Autophagy is involved in the regulation of proliferation, migration and phenotype switching of VSMCs, which in turn affects the pathological process of atherosclerosis. However, the autophagy of VSMCs has a dual effect on cells survival. Autophagy is induced in VSMCs by various stimuli such as 7-ketocholesterol (7-KC), unsaturated lipid peroxidation-derived aldehyde and excess free cholesterol, thereby promoting VSMCs survival and stabilising atherosclerotic plaque. Conversely, autophagy caused by factors such as osteopontin (OPN), angiotensin II (Ang II) and nicotine can accelerate the death of VSMCs, further accelerating atherosclerotic lesions. In addition, mitophagy and lipophagy as selective autophagy are also involved in the outcome of VSMCs as well as progression of atherosclerotic lesion. Currently, there are only a few drugs available to induce VSMCs autophagy, such as atorvastatin, telmisartan and so on. Due to the important role of VSMCs autophagy in the progression of atherosclerosis plaques, drugs that directly target autophagy of VSMCs are urgently needed to be developed.

Identifiants

pubmed: 31835918
doi: 10.1080/1061186X.2019.1705312
doi:

Substances chimiques

Angiotensin II 11128-99-7

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

449-455

Auteurs

Yin-Yu Zhang (YY)

School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
Division of Stem Cell Regulation and Application, Hunan University of Chinese Medicine, Changsha, China.

Ya-Ning Shi (YN)

School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
Division of Stem Cell Regulation and Application, Hunan University of Chinese Medicine, Changsha, China.

Neng Zhu (N)

The First Affiliated Hospital, Hunan University of Chinese Medicine, Changsha, China.

Wei Wang (W)

School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
Division of Stem Cell Regulation and Application, Hunan University of Chinese Medicine, Changsha, China.

Chang-Feng Deng (CF)

School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
Division of Stem Cell Regulation and Application, Hunan University of Chinese Medicine, Changsha, China.

Xue-Jiao Xie (XJ)

College of Chinese Medicine, Hunan University of Chinese Medicine, Changsha, China.

Duan-Fang Liao (DF)

School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
Division of Stem Cell Regulation and Application, Hunan University of Chinese Medicine, Changsha, China.

Li Qin (L)

School of Pharmacy, Hunan University of Chinese Medicine, Changsha, China.
Division of Stem Cell Regulation and Application, Hunan University of Chinese Medicine, Changsha, China.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH